Ethan Neumann was a patient-scientist at Johns Hopkins who dedicated his life to researching fibrolamellar liver cancer, the disease that claimed his life at 27.
A research fellowship is being established in his name to support future scientists. Help honor his legacy.
gofund.me/0f7b2217b
A research fellowship is being established in his name to support future scientists. Help honor his legacy.
gofund.me/0f7b2217b
December 13, 2025 at 12:33 PM
Ethan Neumann was a patient-scientist at Johns Hopkins who dedicated his life to researching fibrolamellar liver cancer, the disease that claimed his life at 27.
A research fellowship is being established in his name to support future scientists. Help honor his legacy.
gofund.me/0f7b2217b
A research fellowship is being established in his name to support future scientists. Help honor his legacy.
gofund.me/0f7b2217b
Ethan Neumann, a 27-year-old PhD candidate in my lab, devoted himself to studying #fibrolamellar carcinoma, the cancer that claimed his life last week.
Please support his father’s effort to establish an endowed research fellowship in Ethan’s name ⬇️
gofund.me/f03f47244
Please support his father’s effort to establish an endowed research fellowship in Ethan’s name ⬇️
gofund.me/f03f47244
Donate to Ethan Neumann Fellowship, organized by Craig Neumann
Ethan Neumann Fellowship
Help establish the Dr. Ethan Neumann Memorial Research Fellowshi… Craig Neumann needs your support for Ethan Neumann Fellowship
www.gofundme.com
December 13, 2025 at 2:47 AM
Ethan Neumann, a 27-year-old PhD candidate in my lab, devoted himself to studying #fibrolamellar carcinoma, the cancer that claimed his life last week.
Please support his father’s effort to establish an endowed research fellowship in Ethan’s name ⬇️
gofund.me/f03f47244
Please support his father’s effort to establish an endowed research fellowship in Ethan’s name ⬇️
gofund.me/f03f47244
We lost someone extraordinary: Ethan Neumann, a PhD candidate in my lab, worked tirelessly to study fibrolamellar carcinoma - the cancer that would ultimately claim his life
Just before his died, he officially earned his doctorate and became Dr. Neumann
→ myarchoan.wixsite.com/yarchoanlabs...
Just before his died, he officially earned his doctorate and became Dr. Neumann
→ myarchoan.wixsite.com/yarchoanlabs...
December 8, 2025 at 2:08 AM
We lost someone extraordinary: Ethan Neumann, a PhD candidate in my lab, worked tirelessly to study fibrolamellar carcinoma - the cancer that would ultimately claim his life
Just before his died, he officially earned his doctorate and became Dr. Neumann
→ myarchoan.wixsite.com/yarchoanlabs...
Just before his died, he officially earned his doctorate and became Dr. Neumann
→ myarchoan.wixsite.com/yarchoanlabs...
The breakthrough builds on work Paul Thomas conducted through a ASPIRE Award granted in partnership with the Fibrolamellar Cancer Foundation. It offers new hope for FLC patients — and a new path forward for therapeutic vaccines targeting so-called “undruggable” cancer drivers.
December 4, 2025 at 9:07 PM
The breakthrough builds on work Paul Thomas conducted through a ASPIRE Award granted in partnership with the Fibrolamellar Cancer Foundation. It offers new hope for FLC patients — and a new path forward for therapeutic vaccines targeting so-called “undruggable” cancer drivers.
From bench to bedside! In a Phase 1 trial, a vaccine targeting a neoantigen in fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer primarily affecting younger people, showed significant clinical benefit when combined with immune checkpoint inhibitors. www.nature.com/articles/s41...
December 4, 2025 at 9:07 PM
From bench to bedside! In a Phase 1 trial, a vaccine targeting a neoantigen in fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer primarily affecting younger people, showed significant clinical benefit when combined with immune checkpoint inhibitors. www.nature.com/articles/s41...
Promising peptide vaccine targeting DNAJ-PKAc yields 75% disease control in advanced fibrolamellar hepatocellular carcinoma patients after initial treatment.
by Baretti M, Kirk AM (...) Yarchoan M et 25 al. in Nat Med #MedSky
👉 get more here
📖 read the article:
by Baretti M, Kirk AM (...) Yarchoan M et 25 al. in Nat Med #MedSky
👉 get more here
📖 read the article:
A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial - Nature Medicine
In this phase 1 trial, treatment of patients with fibrolamellar hepatocellular carcinoma with a therapeutic peptide vaccine targeting the fusion kinase DNAJB1–PRKACA, which is the driver of the disease, together with nivolumab and ipilimumab, was safe and led to encouraging preliminary clinical responses, and translational analysis showed activation of immune responses.
www.nature.com
December 3, 2025 at 6:47 PM
In a phase 1 trial, treatment of fibrolamellar hepatocellular carcinoma with a therapeutic peptide vaccine targeting the DNAJB1::PRKACA fusion, together with nivolumab and ipilimumab, was safe and led to encouraging preliminary clinical responses. https://www.nature.com/articles/s41591-025-03995-y
December 1, 2025 at 1:00 PM
In a phase 1 trial, treatment of fibrolamellar hepatocellular carcinoma with a therapeutic peptide vaccine targeting the DNAJB1::PRKACA fusion, together with nivolumab and ipilimumab, was safe and led to encouraging preliminary clinical responses. https://www.nature.com/articles/s41591-025-03995-y
Damle and Carter et al. integrated spatial proteomics, tissue microarray, multiplex immunofluorescence imaging, and transcriptomics data from highly desmoplastic fibrolamellar carcinoma, and [...] bit.ly/4ohk276
November 28, 2025 at 4:30 PM
Damle and Carter et al. integrated spatial proteomics, tissue microarray, multiplex immunofluorescence imaging, and transcriptomics data from highly desmoplastic fibrolamellar carcinoma, and [...] bit.ly/4ohk276
In a phase 1 trial, treatment of fibrolamellar hepatocellular carcinoma with a therapeutic peptide vaccine targeting the DNAJB1::PRKACA fusion, together with nivolumab and ipilimumab, was safe and led to encouraging preliminary clinical responses. https://www.nature.com/articles/s41591-025-03995-y
November 26, 2025 at 1:01 PM
In a phase 1 trial, treatment of fibrolamellar hepatocellular carcinoma with a therapeutic peptide vaccine targeting the DNAJB1::PRKACA fusion, together with nivolumab and ipilimumab, was safe and led to encouraging preliminary clinical responses. https://www.nature.com/articles/s41591-025-03995-y
A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma @naturemedicine.bsky.social @markyarchoan.bsky.social @hopkinspress.bsky.social @pgtimmune.bsky.social @fredhutch.org @stjude.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
November 25, 2025 at 7:16 PM
A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma @naturemedicine.bsky.social @markyarchoan.bsky.social @hopkinspress.bsky.social @pgtimmune.bsky.social @fredhutch.org @stjude.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial
->Nature | #health #vaccine | More from Lil Dr Glen EcoChat at BigEarthData.ai
->Nature | #health #vaccine | More from Lil Dr Glen EcoChat at BigEarthData.ai
A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial
From April 2020 to September 2022, 16 patients with unresectable FLC were enrolled (Fig. 1a). The clinical characteristics of the enrolled patients are summarized in Table 1. The median age was 23.5 years (range 12–47 years). The majority of patients...
www.nature.com
November 24, 2025 at 11:38 PM
FLC work led by @markyarchoan.bsky.social and TIRTL by @pogorely.bsky.social w/ Marina Baretti Allison Kirk,
Jeremy Crawford, Samir Adhikari, @nick-clark-bioinfo.bsky.social, Anastasia Minervina, David Brice, Stefan Schattgen, Zeal Kamdar, & Balaji Sundararaman, Support Fibrolamellar Cancer Found.
Jeremy Crawford, Samir Adhikari, @nick-clark-bioinfo.bsky.social, Anastasia Minervina, David Brice, Stefan Schattgen, Zeal Kamdar, & Balaji Sundararaman, Support Fibrolamellar Cancer Found.
November 24, 2025 at 9:38 PM
FLC work led by @markyarchoan.bsky.social and TIRTL by @pogorely.bsky.social w/ Marina Baretti Allison Kirk,
Jeremy Crawford, Samir Adhikari, @nick-clark-bioinfo.bsky.social, Anastasia Minervina, David Brice, Stefan Schattgen, Zeal Kamdar, & Balaji Sundararaman, Support Fibrolamellar Cancer Found.
Jeremy Crawford, Samir Adhikari, @nick-clark-bioinfo.bsky.social, Anastasia Minervina, David Brice, Stefan Schattgen, Zeal Kamdar, & Balaji Sundararaman, Support Fibrolamellar Cancer Found.
Two complementary studies from our group out today: a therapeutic peptide vaccine trial for fibrolamellar carcinoma (FLC) & TIRTL-Seq, our robust method for deep quantitative paired TCR sequencing a🧵w/ @markyarchoan.bsky.social & @pogorely.bsky.social www.nature.com/articles/s41...
TIRTL-seq: deep, quantitative and affordable paired TCR repertoire sequencing - Nature Methods
TIRTL-seq is a high-throughput method for paired T cell receptor sequencing at the cohort scale.
www.nature.com
November 24, 2025 at 9:38 PM
Two complementary studies from our group out today: a therapeutic peptide vaccine trial for fibrolamellar carcinoma (FLC) & TIRTL-Seq, our robust method for deep quantitative paired TCR sequencing a🧵w/ @markyarchoan.bsky.social & @pogorely.bsky.social www.nature.com/articles/s41...
An experimental vaccine targeting fibrolamellar carcinoma, a rare liver cancer in young people, demonstrated disease control in 75% of early trial participants and was generally well-tolerated. doi.org/hbcffc
Experimental liver cancer vaccine shows promise for young patients in early trial
An experimental cancer vaccine developed at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy has shown early promise in a Phase I clinical trial for a rare form of liver cancer that primarily affects children and young adults.
medicalxpress.com
November 24, 2025 at 8:50 PM
An experimental vaccine targeting fibrolamellar carcinoma, a rare liver cancer in young people, demonstrated disease control in 75% of early trial participants and was generally well-tolerated. doi.org/hbcffc
6) Immunohistochemistry: PCT is positive in 77% of FLC, but absent in other primary or secondary liver tumors.
In conclusion
👉 serum and tumor PCT = sensitive & specific biomarker for fibrolamellar hepatocellular carcinoma.
In conclusion
👉 serum and tumor PCT = sensitive & specific biomarker for fibrolamellar hepatocellular carcinoma.
November 23, 2025 at 10:59 AM
6) Immunohistochemistry: PCT is positive in 77% of FLC, but absent in other primary or secondary liver tumors.
In conclusion
👉 serum and tumor PCT = sensitive & specific biomarker for fibrolamellar hepatocellular carcinoma.
In conclusion
👉 serum and tumor PCT = sensitive & specific biomarker for fibrolamellar hepatocellular carcinoma.
2) Fibrolamellar carcinoma (FLC) affects young patients and lacks reliable biomarkers (AFP/CA19-9 usually normal). An unexpectedly high PCT level in one case led us to investigate PCT across two cohorts (Europe and USA)
November 23, 2025 at 10:59 AM
2) Fibrolamellar carcinoma (FLC) affects young patients and lacks reliable biomarkers (AFP/CA19-9 usually normal). An unexpectedly high PCT level in one case led us to investigate PCT across two cohorts (Europe and USA)
1) We recently identified as serum tumor biomarker of fibrolamellar carcinoma, procalcitonin, with @zucmanrossi.bsky.social and @markyarchoan.bsky.social that you can find in www.medrxiv.org/content/10.1...
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma
Introduction: Fibrolamellar carcinoma (FLC) is a rare primary liver cancer that predominantly affects young patients with normal known serum tumor biomarkers (alpha-fetoprotein (AFP) and CA19-9). An o...
www.medrxiv.org
November 23, 2025 at 10:59 AM
1) We recently identified as serum tumor biomarker of fibrolamellar carcinoma, procalcitonin, with @zucmanrossi.bsky.social and @markyarchoan.bsky.social that you can find in www.medrxiv.org/content/10.1...
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma https://www.medrxiv.org/content/10.1101/2025.11.18.25340286v1
November 20, 2025 at 4:27 PM
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma https://www.medrxiv.org/content/10.1101/2025.11.18.25340286v1
Nasopharyngeal mass, adult male.
Dx: Hyalinizing clear cell ca.
➡️Nests of eosinophilic and/or clear cells. Helpful: 2 ‘types’ of fibrosis (dense hyalinization and fibrolamellar stromal fibrosis).
#PathSky #ENTsky #HeadNeckSky
Dx: Hyalinizing clear cell ca.
➡️Nests of eosinophilic and/or clear cells. Helpful: 2 ‘types’ of fibrosis (dense hyalinization and fibrolamellar stromal fibrosis).
#PathSky #ENTsky #HeadNeckSky
August 19, 2025 at 10:04 PM
Nasopharyngeal mass, adult male.
Dx: Hyalinizing clear cell ca.
➡️Nests of eosinophilic and/or clear cells. Helpful: 2 ‘types’ of fibrosis (dense hyalinization and fibrolamellar stromal fibrosis).
#PathSky #ENTsky #HeadNeckSky
Dx: Hyalinizing clear cell ca.
➡️Nests of eosinophilic and/or clear cells. Helpful: 2 ‘types’ of fibrosis (dense hyalinization and fibrolamellar stromal fibrosis).
#PathSky #ENTsky #HeadNeckSky
#BrunoSangro discusses #fibrolamellar HCC at #ESMOGI25. Quoting Prof Sangro “This is a call to action since #FLC is a rare disease but shouldn’t be neglected” and I cannot agree more. Post n.2. @myesmo.bsky.social
#ESMOAmbassadors
#ESMOAmbassadors
July 4, 2025 at 1:22 PM
#BrunoSangro discusses #fibrolamellar HCC at #ESMOGI25. Quoting Prof Sangro “This is a call to action since #FLC is a rare disease but shouldn’t be neglected” and I cannot agree more. Post n.2. @myesmo.bsky.social
#ESMOAmbassadors
#ESMOAmbassadors
#BrunoSangro discusses #fibrolamellar HCC at #ESMOGI25. Quoting Prof Sangro “This is a call to action since #FLC is a rare disease but shouldn’t be neglected” and I cannot agree more. Post n.1. @myesmo.bsky.social
#ESMOAmbassadors
#ESMOAmbassadors
July 4, 2025 at 1:22 PM
#BrunoSangro discusses #fibrolamellar HCC at #ESMOGI25. Quoting Prof Sangro “This is a call to action since #FLC is a rare disease but shouldn’t be neglected” and I cannot agree more. Post n.1. @myesmo.bsky.social
#ESMOAmbassadors
#ESMOAmbassadors
We show that the liver cancer fibrolamellar carcinoma is characterized by increased mitochondrial calcium levels, which leads to inhibition of BCAA catabolism. Congratulations to all the authors, and many thanks to collaborators @lucasbsullivan.bsky.social @shaoenong.bsky.social
May 31, 2025 at 6:24 AM
We show that the liver cancer fibrolamellar carcinoma is characterized by increased mitochondrial calcium levels, which leads to inhibition of BCAA catabolism. Congratulations to all the authors, and many thanks to collaborators @lucasbsullivan.bsky.social @shaoenong.bsky.social
Our paper on regulation of BCAA catabolism by mitochondrial calcium signaling is out!
Mitochondrial calcium signaling regulates branched-chain amino acid catabolism in fibrolamellar carcinoma | Science Advances www.science.org/doi/10.1126/...
Mitochondrial calcium signaling regulates branched-chain amino acid catabolism in fibrolamellar carcinoma | Science Advances www.science.org/doi/10.1126/...
Mitochondrial calcium signaling regulates branched-chain amino acid catabolism in fibrolamellar carcinoma
Mitochondrial Ca2+ signaling regulates branched-chain amino acid catabolism in an adolescent liver cancer.
www.science.org
May 31, 2025 at 6:24 AM
Our paper on regulation of BCAA catabolism by mitochondrial calcium signaling is out!
Mitochondrial calcium signaling regulates branched-chain amino acid catabolism in fibrolamellar carcinoma | Science Advances www.science.org/doi/10.1126/...
Mitochondrial calcium signaling regulates branched-chain amino acid catabolism in fibrolamellar carcinoma | Science Advances www.science.org/doi/10.1126/...
Mitochondrial calcium signaling regulates branched-chain amino acid catabolism in fibrolamellar carcinoma
Science Advances
www.science.org/doi/10.1126/...
Science Advances
www.science.org/doi/10.1126/...
Mitochondrial calcium signaling regulates branched-chain amino acid catabolism in fibrolamellar carcinoma
Mitochondrial Ca2+ signaling regulates branched-chain amino acid catabolism in an adolescent liver cancer.
www.science.org
May 30, 2025 at 8:21 PM
Mitochondrial calcium signaling regulates branched-chain amino acid catabolism in fibrolamellar carcinoma
Science Advances
www.science.org/doi/10.1126/...
Science Advances
www.science.org/doi/10.1126/...
Next Thursday, May 15 from 1:30-2:30pm CST, Dr. Sean Ronnekleiv-Kelly will be presenting a hybrid Bio-Tech Talk about "Fibrolamellar Carcinoma and PRKACA Fusion Tumors." Join in person at 425 Henry Mall Room 1111 or via Zoom. For more information: biotech.wisc.edu/bio-tech-tal...
May 8, 2025 at 6:30 PM
Next Thursday, May 15 from 1:30-2:30pm CST, Dr. Sean Ronnekleiv-Kelly will be presenting a hybrid Bio-Tech Talk about "Fibrolamellar Carcinoma and PRKACA Fusion Tumors." Join in person at 425 Henry Mall Room 1111 or via Zoom. For more information: biotech.wisc.edu/bio-tech-tal...